DOCSLIB.ORG

| Hai Lala Mo at Alt a La La La Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
| Hai Lala Mo at Alt a La La La Manual |HAI LALA MO ATUS009938323B2 ALT A LA LA LA MANUAL (12 ) United States Patent ( 10 ) Patent No. : US 9 ,938 , 323 B2 Grunewald et al. (45 ) Date of Patent : Apr . 10 , 2018 ( 54 ) AMATOXIN DERIVATIVES AND WO 2014135282 AL 9 / 2014 CONJUGATES THEREOF AS INHIBITORS WO 2014141094 Al 9 / 2014 OF RNA POLYMERASE WO 2016142049 AL 9 / 2016 (71 ) Applicant: NOVARTIS AG , Basel (CH ) OTHER PUBLICATIONS ( 72 ) Inventors : Jan Grunewald , San Diego , CA (US ) ; Yunho Jin , San Diego , CA (US ) ; Zhao , et al ., “ Synthesis of a Cytotoxic Amanitin for Biorthogonal Weijia Ou , San Diego , CA (US ) ; Conjugation ” , ChemBioChem , 2015 , pp . 1420 - 1425, vol . 16 , Tetsuo Uno , San Diego , CA (US ) Wiley - VCH Verlag GmbH & Co . Adair, et al ., “ Antibody -drug conjugates a perfect synergy ” , ( 73 ) Assignee : Novartis AG , Basel (CH ) Expert Opin . Biol. Ther. , 2012 , pp . 1191 - 1206 , vol. 12 , No . 9 , Informa UK , Ltd . ( * ) Notice : Subject to any disclaimer , the term of this Flygare , et al ., “ Antibody - Drug Conjugates for the Treatment of patent is extended or adjusted under 35 Cancer ” , Chem . Biol . Drug . Des. , 2013 , pp . 113 - 121 , vol. 81 , John Wiley & Sons A / S . U . S . C . 154 ( b ) by 0 days . Jackson , et al ., “ Using the Lessons Learned from the Clinic to Improve the Preclinical Development of Antibody Drug Conju (21 ) Appl. No. : 15 /524 , 197 gates ” , Pharm . Res . , 2014 , pp . 1 - 12 . (22 ) PCT Filed : Nov. 5 , 2015 (Continued ) ( 86 ) PCT No. : PCT/ IB2015 /058537 Primary Examiner — Jeanette Lieb $ 371 ( c ) ( 1 ) , ( 74 ) Attorney , Agent, or Firm — Daniel E . Raymond ; ( 2 ) Date : May 3, 2017 Genomics Institute of the Novartis Research Foundation ( 87) PCT Pub . No. : WO2016 /071856 (57 ) ABSTRACT PCT Pub . Date : May 12 , 2016 The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I ), methods of inhibiting RNA poly (65 ) Prior Publication Data merase with such cyclic peptides , immunoconjugates com US 2017/ 0355731 A1 Dec. 14, 2017 prising such cyclic peptides ( i. e Antibody Drug Conjugates) , pharmaceutical compositions comprising such cyclic pep tides immunoconjugates , compositions comprising such Related U . S . Application Data cyclic peptides immunoconjugates with a therapeutic co (60 ) Provisional application No . 62 /076 ,023 , filed on Nov. agent and methods of treatment using such cyclic peptides 6 , 2014 immunoconjugates: (51 ) Int. Ci. A61K 38 /00 ( 2006 .01 ) Formula ( I ) CO7K 7 /64 ( 2006 . 01 ) COOK 16 / 22 ( 2006 .01 ) HO COOK 16 / 30 ( 2006 .01 ) (52 ) U . S . CI. CO7K 7764 ( 2013 .01 ) ; CO7K 16 / 22 HO (2013 .01 ) ; CO7K 16 / 30 ( 2013 .01 ) ; CO7K 2319 / 30 (2013 .01 ) HN (58 ) Field of Classification Search None See application file for complete search history. 12Omn ( 56 ) References Cited HO FOREIGN PATENT DOCUMENTS EP 2774624 Al 10 / 2014 ' S - R2 EP 2683409 B1 12 / 2014 wo 2009114950 A1 9 / 2009 WO 2010115629 A2 10 / 2010 O WO 2011014973 A2 2 / 2011 WO 2012016186 A2 2 / 2012 WO 2012041504 A1 4 / 2012 WO 2012119787 A1 9 /2012 WO 2013104613 A1 7 / 2013 WO 2014009025 A1 1 / 2014 wo 2014043403 A13 / 2014 23 Claims, 7 Drawing Sheets US 9 ,938 ,323 B2 Page 2 ( 56 ) References Cited OTHER PUBLICATIONS Konig , et al. , “ Chemistry of Peptides and Proteins” , Proceeding sof the Sixth USSR -FRG Symposium on Chemistry of Peptides and PRoteins, Sep . 1 - 5 , 1987 . Moldenhauer , et al. , “ Therapeutic Potential of Amanitin -Conjugated Anti - Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Cacinoma” , JNCI, Apr . 18 , 2012 , pp . 622 -634 , vol. 104 , Issue 8 , Oxford University Press . Senter , et al ., “ The discovery and development of brentuximab vedotin for use in relapsed Hogkin lymphoma and systemic anaplastic large cell lymphoma” , Nature Biotechnology , Jul. 6372012 , pp . 631 -637 , vol . 30 , Nature America , Inc. U. S . Patentatent Apr . 10 , 2018 Sheet 1 of 7 US 9 , 938 ,323 B2 FIG . 1A MDA -MB - 231 clone 40 - - - anti -Her2 - LC -S159C -21 5 o anti -Her2 -LC - S159C - 45 th + anti -Her2 - LC - S159C - 11 ! A anti- Her2 - LC -S159C - 18 • anti - Her2 - LC - S159C - 17 o anti- Her2 - LC - S159C - 22 - o - anti- Her2 - LC -S159C - 4 Normalizedviability 0 - anti- Her2 - LC -S159C - 32 * - anti -Her2 - LC - S159C - 23 # anti -Her2 - LC - S159C - 13 - - anti -Her2 - 16 1. E -07 1 . E - 06 1 . E -05 1 . E - 04 1 . E -03 1 . E -02 1 . E - 01 ADC concentration (UM ) FIG . 1B MDA - MB -231 clone 16 • anti -Her2 - LC - S159C - 21 o anti -Her2 -LC -S159C - 45 + anti- Her2 -LC -S159C - 11 A anti -Her2 - LC - S159C - 18 + anti -Her2 - LC - S159C - 17 Normalizedviability o anti- Her2 - LC - S159C -22 - o - anti -Her2 - LC - S159C - 4 anti - Her2 - LC - S159C - 32 Hoo- oo * anti- Her2 -LC -S159C -23 LETU + anti- Her2- LC - S159C - 13 * B S anti- Her2 -16 1. E - 07 1 . 6 - 06 1. 6 -05 1 . 5 -04 1. E -03 1. E -02 1 . 5 -01 ADC concentration (uM ) U . S . Patent Apr . 10 , 2018 Sheet 2 of 7 US 9 , 938 ,323 B2 FIG . 1C HCC1954 anti -Her2 -LC - S159C - 21 o anti - Her2 -LC - S159C - 45 Tab*XD + anti -Her2 -LC - S159C - 11 A anti -Her2 -LC - S159C - 18 anti- Her2 - LC - S159C - 17 o anti- Her2 - LC - S159C - 4 o anti -Her2 -LC - S159C - 22 Normalizedviability 0 - anti- Her2 - LC - S159C -32 * anti - Her2 - LC - S159C - 23 + anti -Her2 -LC - S159C - 13 anti - Her2 - 16 1 . E - 07 1 . E -06 1 . E - 05 1. E - 04 1 . E - 03 1 . E -02 1 . E -01 ADC concentration (uM ) FIG. Jim T - 1 - * * * anti- Her2 - LC - S159C - 21 anti- Her2 - LC - S159C - 45 + anti -Her2 -LC - S159C - 11 De A anti- Her2 - LC -S159C - 18 Home anti- Her2 - LC - S159C - 17 - - - anti- Her2 - LC - S159C - 4 o anti- Her2 - LC - S159C - 22 Normalizedviability 0 - anti- Her2 -LC - S159C - 32 * anti- Her2 - LC -S159C - 23 + anti- Her2 - LC - S159C - 13 - - - anti- Her2 - 16 1 . E -07 1 . E - 06 1 . 6 -05 1 . E -04 1 . E -03 1 . E -02 1 . E -01 ADC concentration (UM ) atent Apr . 10 , 2018 Sheet 3 of 7 US 9 , 938 ,323 B2 FIG . 2A Jim T - 1 1 . 2 anti- HER2 -HC -E388 -DS -ppan - CoA - 1 -40 -LEFIASKLA -N389 2 _ anti- HER2 - HC - E388 -DS -ppan - COA - 1 -39 - LEFIASKLA -N389 Normalizedviability J A anti -HER2 -HC -E388 - DS - ppan -CoA - 1 -41 -LEFIASKLA - N389 anti- HER2 -HC - E388 - DS -ppan - CoA - 1- 9 -40 -LEFIASKLA -N389 0 . 2 0 - anti- HER2 -HC -E388 -DS -ppan -CoA -1 - 9 -39 - LEFIASKLA -N389 A anti- HER2 -HC - E388 -DS -ppan - CoA - 1- 9 -41 -LEFIASKLA -N389 0 . 0 + 1. E -07 1. E - 06 1. E - 05 1 . 5 -04 1 . E -03 1 . E - 02 1 . E -01 ADC concentration (UM ) FIG . 2B A375 anti- HER2 - HC -E388 - DS -ppan -CoA - 1 -40 - LEFIASKLA -N389 + anti- HER2 - HC - E388 -DS -ppan - CoA - 1 - 39- LEFIASKLA -N389 Normalizedviability + anti- HER2 -HC - E388 -DS -ppan - CoA - 1 -41 -LEFIASKLA -N389 anti- HER2 - HC - E388 -DS -ppan - CoA - i- 9 - 40 -LEFIASKLA -N389 0 - anti- HER2 - HC - E388 -DS -ppan - CoA -1 - 9 -39 -LEFIASKLA -N389 A - anti- HER2 - HC -E388 -DS - ppan -CoA -i - 9 -41 - LEFIASKLA -N389 0 . 0 + 1 . E -07 1 . E - 06 1 . E - 05 1 . E - 04 1 . E -03 1 . E -02 1 . E -01 ADC concentration (UM ) atent Apr . 10 , 2018 Sheet 4 of 7 US 9 , 938 ,323 B2 FIG . 2C NCI- H526 anti -HER2 - HC - E388 -DS - ppan - COA - 1 -40 -LEFIASKLA -N389 + - anti- HER2- HC - E388 -DS -ppan - CoA - 1 - 39 -LEFIASKLA - N389 + anti -HER2 -HC - E388 -DS -ppan - CoA - 1 -41 -LEFIASKLA -N389 anti- HER2 -HC - E388 - DS - ppan -CoA - i- 9 - 40 -LEFIASKLA -N389 ñ anti- HER2 -HC -E388 - DS -ppan - CoA -i - 9 - 39 - LEFIASKLA -N389 ñ A - anti- HER2 -HC -E388 - DS -ppan -CoA - 1- 9 - 41 -LEFIASKLA -N389 ü Normalizedviability ö å 0 . 0 1 . E - 07 1. E - 06 1. E -05 1 . 5 - 04 1. E -03 1 . E - 02 1. 5 -01 ADC concentration (UM ) FIG . 2D HCC1954 anti- HER2 -HC - E388 -DS -ppan -CoA - 1 - 40 LEFIASKLA -N389 Ötodo - anti -HER2 -HC - E388 -DS - ppan - CoA - 1 - 39 LEFIASKLA -N389 - anti-HER2 - HC -E388 -DS - ppan - CoA - 1- 41 LEFIASKLA -N389 - anti- HER2 -HC - E388 - DS -ppan - CoA - 1 - 9 - 39 Normalizedviability LEFIASKLA -N389 SA anti- HER2 - HC -E388 - DS - ppan -CoA -i - 9 -41 TTTTTT LEFIASKLA -N389 0 . 0 + 1 . E -07 1. 5 -06 1 . E -05 1 .E - 04 1 . 5 -03 1. E -02 1 .E -01 ADC concentration (UM ) U .S . Pateatent Apr . 10 , 2018 Sheet 5 of 7 US 9 , 938 ,323 B2 FIG . 2E NCI- N87 anti- HER2 -HC -E388 -DS -ppan -CoA - 1 -40 LEFIASKLA -N389 anti- HER2 -HC -E388 - DS -ppan - CoA - 1 - 39 LEFIASKLA -N389 anti -HER2 - HC - E388 -DS -ppan -CoA - 1 -41 LEFIASKLA -N389 o anti- HER2 -HC - E388 - DS -ppan - CoA -i - 9 - 39 Normalizedviability LEFIASKLA -N389 1. E -07 1. 6 - 06 1. 6 - 05 1. 5 - 04 1. E -03 1. E -02 1. - 01 ADC concentration (uM ) FIG . 2F SK -BR - 3 - anti- HER2 -HC - E388 -DS -ppan -CoA - 1 - 40 LEFIASKLA -N389 anti- HER2 -HC - E388 -DS - ppan -CoA - 1 - 39 LEFIASKLA -N389 + anti- HER2 - HC - E388 -DS -ppan - COA - 1 - 41 LEFIASKLA -N389 anti- HER2 -HC -E388 -DS -ppan - CoA - i- 9 - 39 Normalizedviability II LEFIASKLA -N389 ASES 1. E - 07 1. 5 - 06 1 . 6 -05 1. -04 1. 5 -03 1 . -02 1. -01 ADC concentration (MM ) atent Apr . 10 , 2018 Sheet 6 of 7 US 9 , 938 ,323 B2 FIG .
Load more

Recommended publications
  • Meeting Key Synthetic Challenges in Amanitin Synthesis with a New Cytotoxic Analog: 50-Hydroxy- Cite This: Chem
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Meeting key synthetic challenges in amanitin synthesis with a new cytotoxic analog: 50-hydroxy- Cite this: Chem. Sci., 2020, 11, 11927 0 † All publication charges for this article 6 -deoxy-amanitin have been paid for by the Royal Society of Chemistry Alla Pryyma, Kaveh Matinkhoo, Antonio A. W. L. Wong and David M. Perrin * Appreciating the need to access synthetic analogs of amanitin, here we report the synthesis of 50-hydroxy- Received 29th July 2020 60-deoxy-amanitin, a novel, rationally-designed bioactive analog and constitutional isomer of a-amanitin, Accepted 2nd October 2020 that is anticipated to be used as a payload for antibody drug conjugates. In completing this synthesis, we DOI: 10.1039/d0sc04150e meet the challenge of diastereoselective sulfoxidation by presenting two high-yielding and rsc.li/chemical-science diastereoselective sulfoxidation approaches to afford the more toxic (R)-sulfoxide. drug-tolerant cell subpopulations.7 Examples include ADCs for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction targeting human epidermal growth factor receptor 2 and pros- 8 9 a-Amanitin, the deadliest of the amatoxins produced by the tate specic membrane antigen. With but a few exceptions, death-cap mushroom Amanita phalloides, is a potent, orally nearly all bioconjugates to a cytotoxic amanitin have emerged 1 a available inhibitor of RNA polymerase II (pol II) (Ki 10 nM), from naturally-sourced -amanitin. To date, conjugation that has been validated as a payload for targeted cancer handles used for a-amanitin-based bioconjugates include the d- 2a therapy.2 First described in 1907 3 and isolated in 1941,4 a- hydroxyl of (2S,3R,4R)-4,5-dihydroxyisoleucine (DHIle), the 10 0 amanitin is a compact bicyclic octapeptide that has been asparagine side chain, and the 6 -hydroxyl of the tryptathio- 11 indispensable for probing RNA pol II-catalysed transcription in nine staple.
    [Show full text]
  • WSC 2000-01 Conference 1
    The Armed Forces Institute of Pathology Department of Veterinary Pathology WEDNESDAY SLIDE CONFERENCE 2002-2003 CONFERENCE 17 12 February 2003 Conference Moderator: LTC Gary Zaucha, DVM Diplomate, ACVP, ABT, and ACVPM Chief, Department of Comparative Pathology Walter Reed Army Institute of Research Silver Spring, MD 20910 CASE I – 1614-1 (AFIP 2850109) Signalment: 5-month-old outbred female Swiss-Webster mouse History: Sentinel mouse in a laboratory colony housed on dirty bedding from other mouse cages, part of an infectious disease surveillance program. Euthanized due to lethargy and unthriftiness. Gross Pathology: Stomach distended approximately three times by gas, fluid, and partially digested food. Kidneys shrunken, pale, and pitted. Multifocal hemorrhagic necrosis and thrombosis of the ovaries bilaterally. Laboratory Results: Negative for all murine infectious pathogens tested in the colony surveillance program by serology, respiratory and intestinal cultures, fecal examination, anal tape, and skin scrapings. Contributor’s Morphologic Diagnosis: Kidney: Chronic nephropathy characterized by membranous glomerulopathy, lymphoplasmacytic adventitial vasculitis and perivasculitis, tubular degeneration, ectasia, and regeneration with protein, hemoglobin, cellular, waxy, and granular casts, and lymphoplasmacytic and histiocytic interstitial nephritis, severe. Contributor’s Comment: This case is consistent with the previously reported syndrome of gastric dilatation and chronic nephropathy in mice exposed to dirty bedding [1]. Although the mean age of affected mice in the published report was 10 months, similar lesions are sometimes found in animals as young as 3 or 4 months of age. The kidney disease appears immune-mediated and is presumably the result of chronic high antigen exposure, although there may be more than one inciting process.
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • Conference 1 C O N F E R E N C E 16 29 January 2020 18 August, 2021 Dr
    Joint Pathology CeJointnter Pathology Center Veterinary PatholVeterinaryogy Service Pathologys Services WEDNESDAY SLIDE CONFERENCE 2021-2022 WEDNESDAY SLIDE CONFER ENCE 2019-2020 Conference 1 C o n f e r e n c e 16 29 January 2020 18 August, 2021 Dr. Ingeborg Langohr, DVM, PhD, DACVP Professor Department of Pathobiological Sciences Louisiana S tate University School of Veterinary Medicine Baton RouJointge, L APathology Center Silver Spring, Maryland CASE I: CASE S1809996 1: 1 ((4152313JPC 4135077-00) ). Microscoptan/purple.ic Descr ipThetio n:medullary The inte rstitparenchymaium was within thedisrupted section isby diff dozensusel yof infilt brightra tedred btoy dull purple SignalmeSignalment:nt: A 3-mont h-old, male, mixed- moderate linesto lar thatge radiatednumbers from of pre thedomi levelna ofntl they renal crest breed pig 6(-Susmonth scrofa-old )male (intact) mastiff (Canis mononuclethroughar cell thes a lonmedulla.g with edema. There familiaris). is abunda nt type II pneumocyte hyperplasia History: This pig had no previous signs of lining alveolar septae and many of the illness, andHistory: was found dead. The patient was referred to a veterinary medicalalveola r spaces have central areas of Gross Patholteachingogy : hospitalApprox imfollowingately 70% an o facute, 1-dayne- crotic macrophages admixed with other the lungs,history primar ofily lethargy in the c andrani ainappetencel regions o fthat quicklymononucle ar cells and fewer neutrophils. the lobes, progressedwere patch toy obtundation. dark red, and Bloodwork firm performedOc casionally there is free nuclear basophilic comparedat to thethe rDVMmore norevealedrmal ar etooas ofhigh lun tog. read ALT, elevated ALP (805 U/L), hypoalbuminemia (2.7 Laboratorg/dL)y re suandlts: hypoglycemia Porcine reprodu (23 cmg/dL).tive PT and and respiraaPTTtory weresyndrome both prolonged (PRRS) PCat >100R wa secs and >300 positive frsec,om sprespectively.lenic tissue, Protein and P RandRS IHCbilirubin were was strongdetectedly immunore on a urineactive dipstick.
    [Show full text]
  • Poisonous Mushrooms; a Review of the Most Common Intoxications A
    Nutr Hosp. 2012;27(2):402-408 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Poisonous mushrooms; a review of the most common intoxications A. D. L. Lima1, R. Costa Fortes2, M. R.C. Garbi Novaes3 and S. Percário4 1Laboratory of Experimental Surgery. University of Brasilia-DF. Brazil/Paulista University-DF. Brazil. 2Science and Education School Sena Aires-GO/University of Brasilia-DF/Paulista University-DF. Brazil. 3School of Medicine. Institute of Health Science (ESCS/FEPECS/SESDF)/University of Brasilia-DF. Brazil. 4Institute of Biological Sciences. Federal University of Pará. Brazil. Abstract HONGOS VENENOSOS; UNA REVISIÓN DE LAS INTOXICACIONES MÁS COMUNES Mushrooms have been used as components of human diet and many ancient documents written in oriental coun- Resumen tries have already described the medicinal properties of fungal species. Some mushrooms are known because of Las setas se han utilizado como componentes de la their nutritional and therapeutical properties and all over dieta humana y muchos documentos antiguos escritos en the world some species are known because of their toxicity los países orientales se han descrito ya las propiedades that causes fatal accidents every year mainly due to medicinales de las especies de hongos. Algunos hongos misidentification. Many different substances belonging to son conocidos por sus propiedades nutricionales y tera- poisonous mushrooms were already identified and are péuticas y de todo el mundo, algunas especies son conoci- related with different symptoms and signs. Carcino- das debido a su toxicidad que causa accidentes mortales genicity, alterations in respiratory and cardiac rates, cada año, principalmente debido a errores de identifica- renal failure, rhabidomyolisis and other effects were ción.
    [Show full text]
  • AMATOXINS in EDIBLE MUSHROOMS H. FAULSTICH* And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 64, number I FEBS LETTERS April 1976 AMATOXINS IN EDIBLE MUSHROOMS H. FAULSTICH* and M. COCHET-MEILHAC** Max-Planck-Institut fiir medizinische Forschungp Abteilung Naturstoff-Chemie, Jahnstr. 29, D-69 Heidelberg, F. R. G., and **Institut de Chimie Biologique, Unit& de Recherche sur le Cancer de I’INSERM et Centre de Neurochimie du C.N.R.S., FacultP de Midecine, F-67085 Strasbourg, France Received 9 February 1976 1. Introduction 2. Materials and methods The toxic cyclopeptides in Amanita phalloides All mushrooms of the Amanita species, except mushrooms weigh about 0.05% of the fresh tissue. A. rubescens and A. pantherina, were harvested near Two-thirds of this weight are phallotoxins, mostly the Trento (Italy) in 1974. The others were collected acidic compounds phallacidin and phallisacin [ 1,2] , near Heidelberg in 1975. The tissues (20-80 g) were the rest being amatoxins, predominantly cr-amanitin. homogenized in a Star mixer together with a two-fold A combination of chromatographic procedures [3] volume of methanol and then kept under stirring at permits the spectrophotometric determination of up 70°C for 1 h. After centrifugation the supernatant to 11 toxic compounds [4] in single mushrooms. The was evaporated in vacua. The residues were thoroughly sensitivity of this analysis is limited to 0.1 pg of each dried, washed with dry ether and dissolved in 2 ml of toxin, this being sufficient, however, to determine 5 water. The amatoxins were extracted from these different amatoxins in A.
    [Show full text]
  • The Effect of a High-Resolution Accurate Mass Spectrometer On
    GÜFBED/GUSTIJ (2020) 10 (4): 878-886 Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi DOI: 10.17714/gumusfenbil.680816 Araştırma Makalesi / Research Article The Effect of A High-Resolution Accurate Mass Spectrometer On Simultaneous Multiple Mushroom Toxin Detection Yüksek Çözünürlüklü Kütle Spektrometrenin Eşzamanlı Çoklu Mantar Toksin Tayinleri Üzerindeki Etkisi Yasemin NUMANOĞLU ÇEVİK*1,2,a 1MoH, Turkish Public Health General Directorate, Microbiology Reference Laboratory, Adnan Saygun Street 55, 06100 Sıhhıye, Ankara, TURKEY 2Separation Science Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 S4-Bis, 9000 Gent, Belgium • Geliş tarihi / Received: 29.01.2020 • Düzeltilerek geliş tarihi / Received in revised form: 17.06.2020 • Kabul tarihi / Accepted: 02.07.2020 Abstract Amatoxins are deadly wild mushroom toxins that cause severe poisoning in humans, from diarrhea to organ dysfunction. Mortality can be as high as 80% if no specific treatment is applied. In this study, separation and determination methods were developed for the simultaneous determination of 7 toxins belonging to Amanita phalloides. After extraction and purification of Amanita phalloides (death cap) wild mushrooms, toxins were detected using HPLC- ESI MS and exact mass with time of flight MS (TOF-MS) in positive ionization mode. In addition, it was observed that the toxins of α- and β-amanitine could be differentiated from each other thanks to HR-MS detection in case of their close retention (Rt) in LC. The presence of two toxins at the same retention point in the chromatogram was detected by differentiating the molecular ion mass (920.3514 DA) of the α-amanitine with the HR-MS (920.3696 DA).
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • Amanita Phalloides Poisoning: Mechanisms of Toxicity and Treatment
    Food and Chemical Toxicology 86 (2015) 41–55 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Review Amanita phalloides poisoning: Mechanisms of toxicity and treatment Juliana Garcia a,∗, Vera M. Costa a, Alexandra Carvalho b, Paula Baptista c,PaulaGuedesde Pinho a, Maria de Lourdes Bastos a, Félix Carvalho a,∗∗ a UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua José Viterbo Ferreiran° 228, 4050-313 Porto, Portugal b Department of Cell and Molecular Biology, Computational and Systems Biology, Uppsala University, Biomedical Center, Box 596, 751 24 Uppsala, Sweden c CIMO/School of Agriculture, Polytechnique Institute of Bragança, Campus de Santa Apolónia, Apartado 1172, 5301-854 Bragança, Portugal article info abstract Article history: Amanita phalloides, also known as ‘death cap’, is one of the most poisonous mushrooms, being involved Received 10 April 2015 in the majority of human fatal cases of mushroom poisoning worldwide. This species contains three main Received in revised form 8 September 2015 groups of toxins: amatoxins, phallotoxins, and virotoxins. From these, amatoxins, especially α-amanitin, Accepted 10 September 2015 are the main responsible for the toxic effects in humans. It is recognized that α-amanitin inhibits RNA Available online 12 September 2015 polymerase II, causing protein deficit and ultimately cell death, although other mechanisms are thought Keywords: to be involved. The liver is the main target organ of toxicity, but other organs are also affected, especially Amanita phalloides the kidneys. Intoxication symptoms usually appear after a latent period and may include gastrointestinal Amatoxins disorders followed by jaundice, seizures, and coma, culminating in death.
    [Show full text]
  • Protein-Polymer-Drug Conjugates
    (19) TZZ¥ ¥ _T (11) EP 3 228 325 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.10.2017 Bulletin 2017/41 A61K 47/59 (2017.01) A61K 47/68 (2017.01) A61K 47/64 (2017.01) A61P 35/00 (2006.01) (21) Application number: 17159707.3 (22) Date of filing: 11.06.2012 (84) Designated Contracting States: • THOMAS, Joshua D AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Natick, MA Massachusetts 01760 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAMMOND, Charles E PL PT RO RS SE SI SK SM TR Billerica, MA Massachusetts 01821 (US) • STEVENSON, Cheri A (30) Priority: 10.06.2011 US 201161495771 P Haverhill, MA Massachusetts 01832 (US) 24.06.2011 US 201161501000 P • BODYAK, Natalya D 29.07.2011 US 201161513234 P Boston, MA 02135 (US) 05.12.2011 US 201161566935 P • CONLON, Patrick R 01.03.2012 US 201261605618 P Wakefield, MA Massachusetts 01880 (US) 30.03.2012 US 201261618499 P • GUMEROV, Dmitry R Waltham, MA Massachusetts 02451 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Cooley (UK) LLP 12728014.7 / 2 717 916 Dashwood 69 Old Broad Street (71) Applicant: Mersana Therapeutics, Inc. London EC2M 1QS (GB) Cambridge, MA 02139 (US) Remarks: (72) Inventors: •Claims f iled aft er the date of fil ing of the • YURKOVETSKIY, Aleksandr application/after the date of receipt of the divisional Littleton, MA Massachusetts 01460 (US) application (Rule 68(4) EPC) • YIN, Mao •This application was filed on 07-03-2017 as a Needham, MA Massachusetts 02492 (US) divisional application to the application mentioned • LOWINGER, Timothy B under INID code 62.
    [Show full text]
  • Interactions Between Drugs and Chemicals in Industrial Societies. G.L
    © 1987 Elsevier Science Publishers B.V. (Biomedical Division) Interactions between drugs and chemicals in industrial societies. G.L. Plaa, P. du Souich, S. Erill, editors. 255 NEW TRENDS IN MUSHROOM POISONING THEODOR WIELAND Max-Planck-Institut fur medizinische Forschung, Jahnstr. 29 D-6900 Heidelberg (FRG) Among the naturally growing products, mushrooms are suspected to be the most poisonous ones. Some people would not eat any mushrooms; the majority is cautious, and consume only a few species confirmed as absolutely innocuous, although the number of edible mushrooms is much greater than it is commonly assumed. The term "poisonous" is a matter of definition. If one defines a substance as poisonous that after ingestión causes transcient irritation of the stomach abdominal pain, nausea and diarrhea then a considreable number of mushrooms are toxic. If one, however, defines a poison as a substance that, in relatively small amounts, can lead to death, only a few species exist that must be designated poisonous fungi. 95% of all lethal intoxications by ingestión are caused by specimens of the genus Amanita. Before treating the important chapter of mushroom poisoning, I would like to mention those species that in rare cases have been reported to have caused death of patients. A. most recent, amply illustrated treatise on poisonous mushrooms has been compiled by Besl and Bresinzki (1). Traditionally, fatal toxicity has been attributed to the red fly-agaric, Amanita muscaria, the mushroom of fairy tales. The reason for this is perhaps the observation that houseflies that suckled enough of the sweetened sap of the mushroom lost their mobility and eventually died.
    [Show full text]
  • Detection of Α-, Β-, and Γ-Amanitin in Urine by LC-MS/MS Using 15 N10-Α-Amanitin As the Internal Standard
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Toxicon Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 September 15. Published in final edited form as: Toxicon. 2018 September 15; 152: 71–77. doi:10.1016/j.toxicon.2018.07.025. Detection of α-, β-, and γ-amanitin in urine by LC-MS/MS using 15 N10-α-amanitin as the internal standard Nicole L. Abbotta, Kasey L. Hillb, Alaine Garrettc, Melissa D. Carterb, Elizabeth I. Hamelinb,*, and Rudolph C. Johnsonb a.Battelle Memorial Institute at the Centers for Disease Control and Prevention, Atlanta, GA, USA b.Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA c.Oak Ridge Institute of Science and Education Fellow at the Centers for Disease Control and Prevention, Atlanta, USA Abstract The majority of fatalities from poisonous mushroom ingestion are caused by amatoxins. To prevent liver failure or death, it is critical to accurately and rapidly diagnose amatoxin exposure. We have developed an liquid chromatography tandem mass spectrometry method to detect α-, β-, and γ-amanitin in urine to meet this need. Two internal standard candidates were evaluated, 15 including an isotopically labeled N10-α-amanitin and a modified amanitin methionine sulfoxide 15 synthetic peptide. Using the N10-α-amanitin internal standard, precision and accuracy of α- amanitin in pooled urine was ≤5.49% and between 100–106%, respectively, with a reportable range from 1–200 ng/mL. β- and γ-Amanitin were most accurately quantitated in pooled urine using external calibration, resulting in precision ≤17.2% and accuracy between 99 – 105% with calibration ranges from 2.5–200 ng/mL and 1.0–200 ng/mL, respectively.
    [Show full text]